China Touts New Drug for Alleviating COVID-19 Now Undergoing Trials
Ecco le Beta EVO Factory 2024, le trial pronto gara - Motociclismo Fuoristrada
PracticeUpdate
Daily evidence digest
Dr Mikhail N. Kosiborod Discusses DARE-19 Trial Findings on Dapagliflozin
Enrique Santas on X: "DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile 🎯 Do not discontinue SGLT2i in 🏥 for #COVID19 Full slideset available
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications | Saint Luke's Health System
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications | Saint Luke's Health System
Otavio Berwanger on LinkedIn: Our DARE-19 trial (dapagliflozin in 1250 patients with COVID-19 and high…
Click to edit Master title style
Healio: DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19 | Saint Luke's Health System
DARE-19 Trial | PPT
Saint Luke's Mid America Heart Institute and AstraZeneca initiate Phase III DARE-19 trial in COVID-19 patients | Saint Luke's Health System
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial | Therapeutic Innovation & Regulatory Science
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial | Therapeutic Innovation & Regulatory Science
Ecco le Beta EVO Factory 2024, le trial pronto gara - Motociclismo Fuoristrada
DARE-19 Trial | PPT
PDF) Effects of Dapagliflozin on Prevention of Major Clinical Events and Recovery in Patients with Respiratory Failure due to COVID ‐19: The Design and Rationale for the DARE‐19 study
Click to edit Master title style
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial,Therapeutic Innovation & Regulatory Science - X-MOL
ESC 365 - Search
Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients | DAIC
